TG Therapeutics Statistics

Total Valuation

TG Therapeutics has a market cap or net worth of $4.07 billion. The enterprise value is $4.07 billion.

Market Cap	4.07B
Enterprise Value	4.07B

Important Dates

The last earnings date was Monday, August 4, 2025, before market open.

Earnings Date	Aug 4, 2025
Ex-Dividend Date	n/a

Share Statistics

TG Therapeutics has 145.90 million shares outstanding. The number of shares has increased by 11.99% in one year.

Current Share Class	145.90M
Shares Outstanding	145.90M
Shares Change (YoY)	+11.99%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	7.33%
Owned by Institutions (%)	71.68%
Float	135.14M

Valuation Ratios

The trailing PE ratio is 77.25 and the forward PE ratio is 20.02. TG Therapeutics's PEG ratio is 0.17.

PE Ratio	77.25
Forward PE	20.02
PS Ratio	8.96
Forward PS	7.89
PB Ratio	14.64
P/TBV Ratio	14.71
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.17

Financial Ratio History

Enterprise Valuation

EV / Earnings	67.30
EV / Sales	8.96
EV / EBITDA	47.37
EV / EBIT	47.39
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.92.

Current Ratio	3.86
Quick Ratio	2.81
Debt / Equity	0.92
Debt / EBITDA	2.89
Debt / FCF	n/a
Interest Coverage	2.75

Financial Efficiency

Return on equity (ROE) is 26.63% and return on invested capital (ROIC) is 13.06%.

Return on Equity (ROE)	26.63%
Return on Assets (ROA)	9.72%
Return on Invested Capital (ROIC)	13.06%
Return on Capital Employed (ROCE)	16.18%
Revenue Per Employee	$1.34M
Profits Per Employee	$178,870
Employee Count	338
Asset Turnover	0.82
Inventory Turnover	0.50

Taxes

In the past 12 months, TG Therapeutics has paid $5.65 million in taxes.

Income Tax	5.65M
Effective Tax Rate	8.55%

Stock Price Statistics

The stock price has increased by +34.96% in the last 52 weeks. The beta is 1.95, so TG Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.95
52-Week Price Change	+34.96%
50-Day Moving Average	35.55
200-Day Moving Average	34.22
Relative Strength Index (RSI)	30.16
Average Volume (20 Days)	2,795,750

Short Selling Information

The latest short interest is 23.44 million, so 16.07% of the outstanding shares have been sold short.

Short Interest	23.44M
Short Previous Month	24.17M
Short % of Shares Out	16.07%
Short % of Float	17.35%
Short Ratio (days to cover)	15.23

Income Statement

In the last 12 months, TG Therapeutics had revenue of $454.07 million and earned $60.46 million in profits. Earnings per share was $0.36.

Revenue	454.07M
Gross Profit	394.85M
Operating Income	85.85M
Pretax Income	n/a
Net Income	60.46M
EBITDA	85.89M
EBIT	85.85M
Earnings Per Share (EPS)	$0.36

Full Income Statement

Balance Sheet

The company has $251.87 million in cash and $254.53 million in debt, giving a net cash position of -$2.66 million or -$0.02 per share.

Cash & Cash Equivalents	251.87M
Total Debt	254.53M
Net Cash	-2.66M
Net Cash Per Share	-$0.02
Equity (Book Value)	276.43M
Book Value Per Share	1.90
Working Capital	492.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$59.13 million and capital expenditures -$112,000, giving a free cash flow of -$59.24 million.

Operating Cash Flow	-59.13M
Capital Expenditures	-112,000
Free Cash Flow	-59.24M
FCF Per Share	-$0.41

Full Cash Flow Statement

Margins

Gross margin is 86.96%, with operating and profit margins of 18.91% and 13.31%.

Gross Margin	86.96%
Operating Margin	18.91%
Pretax Margin	14.56%
Profit Margin	13.31%
EBITDA Margin	18.92%
EBIT Margin	18.91%
FCF Margin	n/a

Dividends & Yields

TG Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.99%
Shareholder Yield	-11.99%
Earnings Yield	1.49%
FCF Yield	-1.46%

Dividend Details

Analyst Forecast

The average price target for TG Therapeutics is $40.80, which is 46.39% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$40.80
Price Target Difference	46.39%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	38.14%
EPS Growth Forecast (5Y)	95.60%

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on April 30, 2012. It was a reverse split with a ratio of 1:56.25.

Last Split Date	Apr 30, 2012
Split Type	Reverse
Split Ratio	1:56.25

Scores

TG Therapeutics has an Altman Z-Score of 5.1 and a Piotroski F-Score of 3.

Altman Z-Score	5.1
Piotroski F-Score	3